August 2023
-
08.14.2023 Prescription Medicines Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma -
08.01.2023 Pfizer Reports Second-Quarter 2023 Results
July 2023
-
07.27.2023 Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy -
07.21.2023 Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility -
07.19.2023 Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate
June 2023
-
06.28.2023 FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency -
06.27.2023 FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec -
06.26.2023 Research and Pipeline Research Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus -
06.23.2023 Prescription Medicines Medicines FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata -
06.22.2023 Financial Finance Pfizer Declares Third-Quarter 2023 Dividend -
06.20.2023 Prescription Medicines Medicines Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval -
06.20.2023 Financial Finance Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts